eISSN: 1897-4252
ISSN: 1731-5530
Kardiochirurgia i Torakochirurgia Polska/Polish Journal of Thoracic and Cardiovascular Surgery
Current issue Archive About the journal Supplements Abstracting and indexing Contact Instructions for authors
SCImago Journal & Country Rank

3/2018
vol. 15
 
Share:
Share:
more
 
 
abstract:
Review paper

The use of stem cells in ischemic heart disease treatment

Radosław Litwinowicz, Bogusław Kapelak, Jerzy Sadowski, Anna Kędziora, Krzysztof Bartus

Kardiochirurgia i Torakochirurgia Polska 2018; 15 (3): 196-199
Online publish date: 2018/09/24
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Ischemic heart disease is a major cause of death and disabilities worldwide. Unfortunately, not all patients are suitable for direct revascularization. Cell-based therapies may be alternative options because of their potential to promote neovascularisation and endothelial repair, improving myocardial perfusion. The success of cell-based therapies depends on the type of implanted stem cells, delivery method and underlying disease. Several different cell populations including bone marrow-derived mononuclear cells (MNCs), mesenchymal stromal cells (MSCs), CD34+, CD133+, endothelial progenitor cells, adipose-derived mesenchymal stromal cells (ASCs) and stem cells from placenta and umbilical cord have been investigated. Presently, no consensus exists about the best cell type for clinical regenerative therapy. Because the system of coronary arteries in the ischemic area is poor and most of the coronary artery is significantly narrowed or closed, direct implantation of stem cells in the ischemic area of the heart muscle appears an attractive method.
keywords:

ischemic heart disease, stem cells, regenerative medicine

references:
Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, Fonarow GC, Lange RA, Levine GN, Maddox TM. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2014; 64: 1929-1949.
Piątek J, Kędziora A, Konstanty-Kalandyk J, Kiełbasa G, Olszewska M, Wierzbicki K, Milaniak I, Song B, Kapelak B, Darocha T. Coronary artery disease in young adults: who needs surgical revascularization? A retrospective cohort study. In: The Heart Surgery Forum 2016.
Head SJ, Davierwala PM, Serruys PW, Redwood SR, Colombo A, Mack MJ, Morice MC, Holmes DR Jr, Feldman TE, Ståhle E. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. Eur Heart J 2014; 35: 2821-2830.
Piątek J, Konstanty-Kalandyk J, Kędziora A, Hyochan BS, Wierzbicki K, Darocha T, Milaniak I, Kapelak B. Total arterial myocardial revascularization in patients over 70 years old-a new trend in coronary surgery in elderly. Przegl Lek 2016; 73: 813-815.
Konstanty-Kalandyk J, Piatek J, Rudzinski P, Wrobel K, Bartus K, Sadowski J. Clinical outcome of arterial myocardial revascularization using bilateral internal thoracic arteries in diabetic patients: a single centre experience. Interact Cardiovasc Thorac Surg 2012; 15: 979-983.
De Lemos J, Omland T. Chronic Coronary Artery Disease: a Companion to Braunwald’s Heart Disease. E-book. Elsevier Health Sciences 2017.
Fisher SA, Brunskill SJ, Doree C, Mathur A, Taggart DP, Martin-Rendon E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev 2014; 4: CD007888.
Franco WP, Bracey AW, Franco KL, Hufnagel CA, Glogar DH, Kloner RA. Fibroblastic growth factor and infarct size. Ann Intern Med 1980; 93: 637-638.
Folkman J, Long DM. The use of silicone rubber as a carrier for prolonged drug therapy. J Surg Res 1964; 4: 139-42.
Elhami E, Dietz B, Xiang B, Deng J, Wang F, Chi C, Goertzen AL, Mzengeza S, Freed D, Arora RC. Assessment of three techniques for delivering stem cells to the heart using PET and MR imaging. EJNMMI Res 2013; 3: 72.
Pavo N, Charwat S, Nyolczas N, Jakab A, Murlasits Z, Bergler-Klein J, Nikfardjam M, Benedek I, Benedek T, Pavo IJ. Cell therapy for human ischemic heart diseases: critical review and summary of the clinical experiences. J Mol Cell Cardiol 2014; 75: 12-24.
Penicka M, Widimsky P, Kobylka P, Kozak T, Lang O. Images in cardiovascular medicine. Early tissue distribution of bone marrow mononuclear cells after transcoronary transplantation in a patient with acute myocardial infarction. Circulation 2005; 112: e63-e65.
Cheng K, Wu F, Cao F. Intramyocardial autologous cell engraftment in patients with ischaemic heart failure: a meta-analysis of randomised controlled trials. Heart Lung Circulation 2013; 22: 887-894.
Tse HF, Kwong YL, Chan JK, Lo G, Ho CL, Lau CP. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003; 361: 47-49.
Hamano K, Nishida M, Hirata K, Mikamo A, Li TS, Harada M, Miura T, Matsuzaki M, Esato K. Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease. Japan
Circulation J 2001; 65: 845-847.
Konstanty-Kalandyk J, Piątek J, Chrapusta A, Song BH, Urbańczyk-Zawadz-ka M, Ślósarczyk B, Majka M, Kędziora A, Bartuś K, Podolec P. Use of adipose-derived stromal cells in the treatment of chronic ischaemic heart disease: safety and feasibility study. Kardiol Pol (Pol Heart J) 2018; 76: 911-913.
Wróbel K, Song BH, Darocha T, Wróżek M, Kapelak B. Minimally invasive coronary artery bypass as a safe method of surgical revascularization. The step towards hybrid procedures. Adv Interv Cardiol 2017; 13: 320-325.
Litwinowicz R, Bartus K, Drwila R, Kapelak B, Konstanty-Kalandyk J, Sobczynski R, Wierzbicki K, Bartuś M, Chrapusta A, Timek T. In-hospital mortality in cardiac surgery patients after readmission to the intensive care unit: a single-center experience with 10,992 patients. J Cardiothorac Vasc Anesth 2015; 29: 570-575.
Litwinowicz R, Bryndza M, Chrapusta A, Kobielska E, Kapelak B, Grudzien G. Hyperbaric oxygen therapy as additional treatment in deep sternal wound infections – a single center’s experience. Kardiochir Torakochirur Pol 2016; 13: 198-202.
Zlabinger K, Lukovic D, Hemetsberger R, Gugerell A, Winkler J, Mandic L, Traxler D, Spannbauer A, Wolbank S, Zanoni G. Matrix metalloproteinase-2 impairs homing of intracoronary delivered mesenchymal stem cells in a porcine reperfused myocardial infarction: comparison with intramyocardial cell delivery. Front Bioeng Biotechnol 2018; 6: 35.
Henry TD, Pepine CJ, Lambert CR, Traverse JH, Schatz R, Costa M, Povsic TJ, David Anderson R, Willerson JT, Kesten S. The Athena trials: autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction. Catheter Cardiovasc Interv 2017; 89: 169-177.
Stamm C, Westphal B, Kleine HD, Petzsch M, Kittner C, Klinge H, Schümichen C, Nienaber CA, Freund M, Steinhoff G. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003; 361: 45-46.
Yu H, Lu K, Zhu J, Wang JA. Stem cell therapy for ischemic heart diseases. Br Med Bull 2017; 12: 135-154.
Fuchs S, Baffour R, Zhou YF, Shou M, Pierre A, Tio FO, Weissman NJ, Leon MB, Epstein SE, Kornowski R. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol 2001; 37: 1726-1732.
Chacko SM, Khan M, Kuppusamy ML, Pandian RP, Varadharaj S, Selvendi-ran K, Bratasz A, Rivera BK, Kuppusamy P. Myocardial oxygenation and functional recovery in infarct rat hearts transplanted with mesenchymal stem cells. Am J Physiol Heart Circ Physiol 2009; 296: H1263-H1273.
Naseri MH, Madani H, Ahmadi ST, Moshkani MF, Kazemi DS, Hosseinnejad H, Hosseini S, Hekmat S, Hossein ZA, Dehghani M. COMPARE CPM-RMI Trial. Intramyocardial transplantation of autologous bone marrow-derived CD133+ cells and MNCs during CABG in patients with recent MI: a phase II/III, multicenter, placebo-controlled, randomized, double-blind clinical trial. Cell J 2018; 20: 267-277.
Beeres SL, Bax JJ, Dibbets-Schneider P, Stokkel MP, Fibbe WE, van der Wall EE, Schalij MJ, Atsma DE. Intramyocardial injection of autologous bone marrow mononuclear cells in patients with chronic myocardial infarction and severe left ventricular dysfunction. Am J Cardiol 2007; 100: 1094-1098.
Rodrigo SF, van Ramshorst J, Hoogslag GE, Boden H, Velders MA, Cannegieter SC, Roelofs H, Al Younis I, Dibbets-Schneider P, Fibbe WE. Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up. J Cardiovasc Transl Res 2013; 6: 816-825.
Konstanty-Kalandyk J, Piątek J, Kędziora A, Miszalski-Jamka T, Kapelak B, Bartuś K, Darocha T, Drwiła R, Sadowski J. Long-term follow-up after holmium: YAG laser revascularization combined with autologous bone marrow derived stem cells implantation. Przegl Lek 2017; 74: 91-95.
Khan AR, Farid TA, Pathan A, Tripathi A, Ghafghazi S, Wysoczynski M, Bolli R. Impact of cell therapy on myocardial perfusion and cardiovascular outcomes in patients with angina refractory to medical therapy: a systematic review and meta-analysis. Circ Res 2016; 118: 984-993.
Konstanty-Kalandyk J, Piatek J, Miszalski-Jamka T, Rudzinski P, Walter Z, Bartus K, Urbanczyk-Zawadzka M, Sadowski J. The combined use of transmyocardial laser revascularisation and intramyocardial injection of bone-marrow derived stem cells in patients with end-stage coronary artery disease: one year follow-up. Kardiol Pol 2013; 71: 485-492.
Rodriguez AM, Elabd C, Amri EZ, Ailhaud G, Dani C. The human adipose tissue is a source of multipotent stem cells. Biochimie 2005; 87: 125-128.
De Ugarte DA, Alfonso Z, Zuk PA, Elbarbary A, Zhu M, Ashjian P, Benhaim P, Hedrick MH, Fraser JK. Differential expression of stem cell mobilization-associated molecules on multi-lineage cells from adipose tissue and bone marrow. Immunol Lett 2003; 89: 267-270.
Wang L, Deng J, Tian W, Xiang B, Yang T, Li G, Wang J, Gruwel M, Kashour T, Rendell J, Glogowski M, Tomanek B, Freed D, Deslauriers R, Arora RC, Tian G. Adipose-derived stem cells are an effective cell candidate for treatment of heart failure: an MR imaging study of rat hearts. Am J Physiol Heart Circ Physiol 2009; 297: H1020-H1031.
Qayyum AA, Mathiasen AB, Mygind ND, Kuhl JT, Jorgensen E, Helqvist S, Elberg JJ, Kofoed KF, Vejlstrup NG, Fischer-Nielsen A, Haack-Sorensen M, Ekblond A, Kastrup J. Adipose-derived stromal cells for treatment of patients with chronic ischemic heart disease (MyStromalCell Trial): a randomized placebo-controlled study. Stem Cells Int 2017; 2017: 5237063.
Bai X, Alt E. Myocardial regeneration potential of adipose tissue-derived stem cells. Biochem Biophys Res Commun 2010; 401: 321-326.
Schenke-Layland K, Strem BM, Jordan MC, Deemedio MT, Hedrick MH, Roos KP, Fraser JK, Maclellan WR. Adipose tissue-derived cells improve cardiac function following myocardial infarction. J Surg Res 2009; 153: 217-223.
Kastrup J, Schou M, Gustafsson I, Nielsen OW, Mogelvang R, Kofoed KF, Kragelund C, Hove JD, Fabricius-Bjerre A, Heitman M, Haack-Sorensen M, Lund LD, Johansen EM, Qayyum AA. Rationale and design of the first double-blind, placebo-controlled trial with allogeneic adipose tissue-derived stromal cell therapy in patients with ischemic heart failure: a phase II Danish Multicentre Study. Stem Cells Int 2017; 2017: 8506370.
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe